Beta Drugs Ltd. · NSE:BETA
Beta Drugs — Investor Presentation (April 2022)
20 slides from Beta Drugs's investor presentation, Apr 27, 2022
Slide 1: Investor Presentation FY 2021-22
Investor Presentation FY 2021-22
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Formulations and API Plant
Formulations and API Plant Address: Address: KHARUNI-LODHI MAJRA Tashkent region, Bekabad ROAD,VILL.NANDPUR,BADDI- city, Uzbekistan MSG, 174101 DIST-SOLAN (HP) Sirdarya street, 8 WHO- GMP plant & other First Indian Oncology plant international accreditations. in Uzbekistan. Established in Triggered
Slide 4: Unique value propositions
Unique value propositions Differentiated Diversified Oncology Science/Innovation Backwardly Integrated portfolio Strong Future pipeline BDL is among the few Rich product pipeline of Working on companies that work •NDDS 23 products across the value chain •TKIs •Proteasome inhibitors Developed API of
Slide 5: Innovation is driving growth - New product development is our core competency
Innovation is driving growth- New product development is our core competency Expertise in NDDS (New Drug Delivery System) R&D expenditure (Value in Crs) 2.5 Proven experience in managing complex product development- Azacitidine Oral, Ready to Use Gemcitabine & Docetaxel 1.3 Working on FTLs- 1st prod
Slide 6: Healthy Growth across all verticals in FY'22
Healthy Growth across all verticals in FY’22 Domestic Own brand International 67% revenue growth 15% revenue growth 65% revenue growth 67% revenue growth • New product launches • New formulations • 9 New product launches • Geographical expansion • New customer addition & • Added new logos & • New ke
Slide 7: Domestic Own Brand
Domestic Own Brand Finished Formulation Sales (% Growth) % Growth 33% 18% 67% FY 19-20 FY 20-21 FY 21-22
Slide 8: Domestic Own Brand - strong position in the Indian market
Domestic Own Brand Beta drugs Limited has strong position in the Indian market with 110 SKUs. Products are available in major Corporate & Govt hospitals
Slide 9: New Brands Launched in 2021-22
Domestic Own Brand New Brands Launched in 2021-22
Slide 10: Road map for Domestic branded market in FY'23
Road map for Domestic branded market in FY’23 Strengthen Increasing Market penetration Talent acquisition product basket customer base Adding 4 new FTL / FFTL Focus on New hospital Increasing presence in Hiring the best people products entries. tier 2 & tier 3 cities for uncovered territories Focus
Slide 11: International Market
International Market International Market FY 20-21 FY 21-22 Triggered for … Globally represented by our subsidiaries or sales partners in 18 Countries More than 50 products registered
Slide 12: Geographical expansion Plan by FY'25
Geographical expansion Plan by FY’25 LatAm ASIA No. of targeted countries: 5 No. of targeted countries: 9 Total market size: ~ $30 mn Total market size: ~ $15 mn Expected business by FY’25: Expected business by FY’25: $4 mn $ 2 mn AFRICA CIS No. of targeted countries: 8 No. of targeted countries: 5
Slide 13: Strong In-House API Development
Strong In-House API Development Highlights of FY 2021-22 • Received WHO-GMP approval • The company is aggressively working to file its first CEP (Europe) by October 2022 • Captive expansion- Adding 1 more line by Aug’22 and focusing on FY 20-21 FY 21-22 EU GMP. • 13 New products developed in FY21-22
Slide 14: Strong In-House API Development
Strong In-House API Development SOLID TUMOR HEMATOLOGY SUPPORTIVE ANASTROZOLE AZACITIDINE APREPITANT AXITINIB AZACITIDINE- ORAL FOSAPREPITANT BICALUTAMIDE BENDAMUSTINE ZOLEDRONIC ACID DOCETAXEL TRIHYDRATE BORTEZOMIB ENZALUTAMIDE DASATINIB ERLOTINIB HYDROCHLORIDE HYDROXYUREA FULVESTRANT IMATINIB GEFI
Slide 15: Our CRAM Partners
Our CRAM Partners ✓ Partnership with 50+ companies ✓ Partnership expected with 3 more Indian MNC in FY’23 Trusted Partners We value our CRAM partners Sustained growth FY 20-21 FY 21-22 Important clients 1
Slide 16: Healthy growth in Revenue & Profit
Healthy growth in Revenue & Profit REVENUE FY’22 Consolidated FY’21 FY’22 growth (Rs Cr) (Rs Cr) Total revenue 116.12 183.84 58% EBITDA 25.24 43.46 72% EBITDA % 21.7% 23.6% 190 bps PAT 11.7 24.8 112% PAT % 10.10% 13.51% 341 bps 1
Slide 17: Financial performance
Financial performance ------------------------------------- % EBITDA % Operating/ EBITDA 23.6% 21.7% 20.2% 19.7% 18.5% 16.0% 15.8% 14.2% FY'19 FY'20 FY'21 FY'22 FY'19 FY'20 FY'21 FY'22 -------------------------------------------------------------------------------------------------------------------
Slide 18: Solvency Ratio
Solvency Ratio --------------------------------- Debt ratio Debt to equity ratio 0.24 0.21 0.48 0.39 0.15 0.26 0.13 0.21 FY'19 FY'20 FY'21 FY'22 FY'19 FY'20 FY'21 FY'22 -----------------------------------------------------------------------------------------------------------------------------------
Slide 19: FY'23 Road Map
FY’23 Road Map Capacity expansion: • Lypholizer capacity increased to 3 folds in Beta drugs plant • Separate lypholized injectable manufacturing facility for general injectable in Adley formulations plant (Cardiovascular, Antifungal, immunosuppressant) Domestic Market International market API CMO Pl
Slide 20: Innovative product development is a result of our continuous efforts
Innovative product development is a result of our continuous efforts. Contacts Email: info@betadrugslimited.com